NCT07221526已完成不适用
SPO2 VALIDATION STUDY - PHILIPS FAST 2025
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 86
- 试验地点
- 1
- 主要终点
- SPO2 ACCURACY
研究概览
简要总结
Clinical investigation is to validate the SpO2 accuracy of the M1133AX5, M1133AX6, and AlarX4 (nasal ala application) SpO2 sensors under test with the Philips FAST Pulse Oximetry technology.
详细描述
The primary objective of this clinical investigation is to validate the SpO2 accuracy of the M1133AX5, M1133AX6, and AlarX4 (nasal ala application) SpO2 sensors under test with the Philips FAST Pulse Oximetry technology during non-motion conditions over the range of 70-100% SaO2, when compared with the reference SaO2 obtained from CO-Oximetry analysis of arterial blood samples.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants accepted into this study must meet all of the following criteria: Participant must have the ability to understand and provide written informed consent
- •Participant is an adult between 18-50 years of age
- •Participant must be willing and able to comply with study procedures and duration
- •Participant is a non-smoker or who has not smoked within 2 days prior to the study
排除标准
- •Participant is considered as being morbidly obese (defined as BMI >39.5)
- •Compromised circulation (i.e., Raynaud's Syndrome), injury, or physical malformation of fingers, toes, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. Tattoos (e.g. permanent, Henna) or artificial dyes (e.g. spray tan, artificial tanning lotion) in the optical path which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the sites utilized.)
- •Females who are pregnant
- •Females who are trying to get pregnant with confirmation of positive urine pregnancy test
- •Participants who have smoked in the last 2 days or participants who have refrained, for at least 48 hours, with COHb levels >3% as assessed with a Masimo Radical 7 (Rainbow)
- •Participants with known respiratory conditions such as: (self-reported)
- •uncontrolled / severe asthma
- •pneumonia / bronchitis
- •shortness of breath / respiratory distress
- •unresolved respiratory or lung surgery
- •emphysema, COPD, lung disease
- •recent COVID with hospitalization
- •Participants with self-reported heart or cardiovascular conditions such as: (self-reported, except for blood pressure and ECG review)
- •high blood pressure: systolic >140 mmHg or diastolic >90 mmHg on 3 consecutive readings (reviewed during health screen)
- •have had cardiovascular surgery, except successful minor surgery without clinical symptoms (i.e., PFO, PDA) chest pain (angina)
- •heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen)
- •previous heart attack
- •blocked artery
- •unexplained shortness of breath
- •congestive heart failure (CHF)
- •history of stroke
- •transient ischemic attack
- •carotid artery disease
- •myocardial ischemia
- •myocardial infarction
- •cardiomyopathy
- •implantable active medical device such as pacemaker or automatic defibrillator
- •Participants with self-reported health conditions as identified in the Health Assessment Form
- •uncontrolled thyroid disease
- •kidney disease / chronic renal impairment,
- •history of seizures (except childhood febrile seizures)
- •history of unexplained syncope
- •recent history of frequent migraine headaches
- •recent symptomatic head injury (within the last 2 months)
- •cancer requiring chemotherapy, radiation, or current treatment
- •Participants with known clotting disorders (selfreported)
- •history of bleeding disorders or personal history of prolonged bleeding from injury
- •history of blood clots
- •hemophilia
- •current use of blood thinner: prescription or daily use of aspirin
- •Sickle Cell Trait or Disease
- •Participants with self-reported dermatological conditions at sensor application sites
- •severe dermatitis
- •hyperkeratosis
- •nail fungus Participants with severe contact allergies to standard adhesives, latex, silicone or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self-reported)
- •Participants with severe allergies to iodine (only applicable if iodine is used)
- •Participants with severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine)
- •Participants with allergies to ultrasound gel
- •Failure of the Perfusion Index Ulnar/Ulnar+Radial Ratio test (Ratio <0.4)
- •Unwillingness or inability to remove nail polish, nail jewelry, or artificial nails from test digits. Bruised nail bed of test digits.
- 另有 5 项未显示
结局指标
主要结局
SPO2 ACCURACY
时间窗: OCTOBER 2025-JANUARY 2026
Accuracy expressed in Arms of SpO2 measurements obtained from the M1133AX5, M1133AX6, and AlarX4 (nasal ala placement) SpO2 sensors under test with the Philips Pulse Oximetry technology over the range of 70-100% SaO2 in comparison to SaO2 as ground truth.
次要结局
- SPO2 ACCURACY(OCTOBER 2025-JANUARY 2026)
- DIFFERENTIAL MEAN(OCTOBER 2025-JANUARY 2026)
- PIGMENTATION DIFFERENTIAL BIAS(OCTOBER 2025-JANUARY 2026)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
SpO2 Validation Study - Philips FAST 2024Pulse OximetryNCT06484452Philips Clinical & Medical Affairs Global113
已完成
不适用
Clinical Performance Testing of Philips FAST SpO2 With Masimo Pulse Oximetry Sensors Across Skin PigmentationHealthyNCT06148623Masimo Corporation70
终止
不适用
SpO2 Validation Study-Philips OptimusNCT07215429Philips Clinical & Medical Affairs Global24
已完成
不适用
Polso SpO2 Accuracy Validation StudyHypoxiaNCT03735329ChroniSense Medical Ltd.10
尚未招募
不适用
Prospective Study to Validate the Clinical Accuracy of the Norbert Device to Measure Oxygen SaturationHealthyHypoxiaNCT05685654Norbert Health15